CorMedix Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

CorMedix şirketinin toplam hissedar öz sermayesi $58.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $77.6M ve $18.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$46.03m
Eşitlik	US$58.71m
Toplam yükümlülükler	US$18.87m
Toplam varlıklar	US$77.59m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16

Recent updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CRMD 'nin kısa vadeli varlıkları ( $73.2M ) kısa vadeli yükümlülüklerini ( $18.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: CRMD şirketinin kısa vadeli varlıkları ( $73.2M ) uzun vadeli yükümlülüklerini ( $393.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CRMD borçsuzdur.

Borcun Azaltılması: CRMD un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CRMD şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CRMD tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

CorMedix Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Recent updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

CorMedix Inc. to Report Q3, 2024 Results on Oct 30, 2024

CorMedix: Delayed Approval, Low Cash, Good Prospects

CorMedix Inc., Annual General Meeting, Nov 21, 2024

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Inc. to Report Q2, 2024 Results on Aug 14, 2024

CorMedix Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

CorMedix Inc. to Report Q1, 2024 Results on May 09, 2024

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)

New minor risk - Share price stability

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

CEO & Director recently bought US$51k worth of stock

Forecast breakeven date moved forward to 2025

CorMedix Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 7.0% to US$13.25

CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath

Cormedix Inc. Announces Commercial and Operational Updates

Forecast to breakeven in 2026

CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts

CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023

CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2022)

CorMedix Inc. to Report Q3, 2023 Results on Nov 14, 2023

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Inc., Annual General Meeting, Oct 26, 2023

Cormedix Inc. Announces Resignation of Paulo F. Costa as Member of the Board of Directors, Effective as of October 15, 2023

Price target decreased by 18% to US$13.75

First half 2023 earnings released: US$0.49 loss per share (vs US$0.38 loss in 1H 2022)

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc. to Report Q2, 2023 Results on Aug 08, 2023

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Announces Resubmission of New Drug Application for Defencath

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in 1Q 2022)

CorMedix Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Cormedix Inc. Announces Promotions in Commercial and Tech Ops

CEO & Director recently bought US$76k worth of stock

Price target increased to US$15.00

High number of new and inexperienced directors

Price target increased to US$15.00

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)

CorMedix Inc. to Report Q3, 2022 Results on Nov 10, 2022

CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

CorMedix Inc., Annual General Meeting, Oct 13, 2022

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in 2Q 2021)

Consensus forecasts updated

CorMedix Inc. Announces Regulatory and Manufacturing Updates

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

CorMedix Inc. to Report Q2, 2022 Results on Aug 11, 2022

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 2000 Dynamic Index

High number of new and inexperienced directors

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CorMedix Inc. Announces Executive Changes

CorMedix Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Price target decreased to US$22.00

No longer forecast to breakeven

CorMedix Inc. Announces Formation of New Scientific Advisory Board

Consensus forecasts updated

No longer forecast to breakeven

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Resubmits the New Drug Application for DefenCath to Address the Complete Response Letter Issued by the U.S. Food and Drug Administration

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely